|
1. BIOLOGIE
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
|
Analysis of human genomes in the cloud [EMBL]
|
|
|
|
|
|
Main advantages of the new tool, called Butler, are continuous system monitoring and its ability to self-heal in case of failure, allowing for 43% more efficient data processing than previous approaches. The tool was developed for the Pan-Cancer project. The team published the method in Nature Biotechnology.
|
|
|
|
|
|
|
|
2.14 ETIOLOGIE - TALC
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
Ultrasound Can Selectively Kill Cancer Cells [Caltech]
|
|
|
|
|
|
If ultrasound can be used to cause cell death in a way that the body's immune system recognizes as injury, instead of as apoptosis, this could lead to the site of the tumor being flooded with white blood cells that could attack remaining cancer cells.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.2.1 IMMUNOTHÉRAPIES CAR-NK
|
|
|
|
|
CAR NK Cells Demonstrate Encouraging Preliminary Results, Study Shows [AJMC]
|
|
|
|
|
|
Anti-CD19 chimeric antigen receptor natural killer (CAR NK) cells, derived from donor umbilical cord blood, produced a 73% objective response rate in 11 patients with lymphoid tumors who received just 1 dose of the infused therapy, with no occurrences of cytokine release syndrome or neurotoxicity, in preliminary study results out of MD Anderson.
|
|
|
|
|
|
|
5.12.2.2 IMMUNOTHÉRAPIES - CAR-T CRISPR
|
|
|
|
|
|
Cutting-edge CRISPR gene editing appears safe in three cancer patients [Science]
|
|
|
|
|
|
For these pioneers, the benefits were limited: One has since died, and the disease has worsened in the others. But the clinical trial, which underwent years of regulatory scrutiny, wasn’t designed to try to cure cancer, says Carl June, a cancer researcher at the University of Pennsylvania (UPenn) who co-led the work. Rather, its goal was to show that the strategy appeared feasible and safe.
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.16 TRAITEMENTS - CHIRURGIE
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.2 IMPLANTS MAMMAIRES
|
|
|
|
6.7.2 APPLIS
|
|
|